The raised guidance and strong royalty growth confirm the core business momentum, but the $5.1B debt overhang and declining net profit cap the upside. Watch for Rina-S and petosemtamab Phase 3 data readouts as key catalysts; the AbbVie trade secret litigation resuming in district court is a medium-term risk.
Price Chart
Executive Summary
Genmab reported strong H1 2026 results with revenue up 25% YoY to $2,051M, driven by DARZALEX and Kesimpta royalties and EPKINLY sales. The company raised its full-year 2026 revenue guidance to $4.325-4.525B (from $4.065-4.395B) and adjusted operating profit guidance to $1.065-1.385B (from $0.900-1.400B). Positive Phase 3 data for epcoritamab in DLBCL and progress on Rina-S and petosemtamab support the pipeline, but net profit declined to $356M from $531M due to higher interest expense from the Merus acquisition debt and increased operating costs.
Key Facts
- Revenue increased 25% YoY to $2,051M for H1 2026.
- Full-year 2026 revenue guidance raised to $4.325-4.525B (midpoint $4.425B).
- Full-year 2026 adjusted operating profit guidance raised to $1.065-1.385B (midpoint $1.225B).
- DARZALEX royalties rose 20% to $1,306M; Kesimpta royalties rose 31% to $259M.
- EPKINLY/TEPKINLY global net sales grew 48% to $312M.
- Phase 3 EPCORE DLBCL-4 trial for epcoritamab met primary endpoint (improved PFS).
- Net profit declined to $356M from $531M due to $217M in interest/amortization expense on borrowings.
- Debt of $5.135B remains from the Merus acquisition; Term B Loan interest margin reduced from 3.00% to 2.00%.
Financial Impact
Revenue up 25% to $2,051M; net profit down 33% to $356M; guidance raised by ~$195M at midpoint for revenue and ~$75M for adjusted operating profit.
Risk Factors
- $5.1B debt from Merus acquisition creates interest expense drag on net profit.
- AbbVie trade secret litigation over Rina-S could resume in district court after ITC withdrawal.
- Chugai patent infringement complaint in Japan over EPKINLY poses potential sales disruption.
- High operating expense growth (28% adjusted) may pressure margins if revenue growth slows.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001434265-26-000108 |
| Document: 0001434265-26-000108-index-headers.html | 0001434265-26-000108 |
| Document: 0001434265-26-000108-index.html | 0001434265-26-000108 |
| Document: 0001434265-26-000108.txt | 0001434265-26-000108 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 8, 2026 24d ago | 6-K | $33.53 $32.65 | ▼ −2.62% | ▼ −1.96% | $34.51 (+2.94%) |
Aug 12, 2026 7w ago | 6-K | $31.42 $34.11 | ▲ +8.56% | ▲ +9.01% | $34.51 (+9.85%) |
Aug 11, 2026 7w ago | 6-K | $30.85 $32.96 | ▲ +6.84% | ▲ +7.24% | $34.51 (+11.88%) |
Aug 6, 2026 8w ago | 6-K | $29.83 $31.34 | ▲ +5.06% | ▲ +3.85% | $34.51 (+15.71%) |
Jul 15, 2026 11w ago | 6-K | $29.08 $28.85 | ▼ −0.79% | ▲ +0.19% | $34.51 (+18.69%) |
Jun 29, 2026 13w ago | 6-K | $27.47 $28.01 | ▲ +1.97% | ▲ +1.36% | $34.51 (+25.65%) |
Jun 17, 2026 15w ago | 6-K | $25.39 $25.87 | ▲ +1.87% | ▲ +2.91% | $34.51 (+35.94%) |
Jun 16, 2026 15w ago | 6-K | $24.74 $25.94 | ▲ +4.85% | ▲ +7.08% | $34.51 (+39.51%) |
Jun 15, 2026 15w ago | 6-K | $24.58 $25.61 | ▲ +4.19% | ▲ +5.57% | $34.51 (+40.42%) |
Jun 15, 2026 15w ago | 6-K | $24.58 $25.61 | ▲ +4.19% | ▲ +5.57% | $34.51 (+40.42%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access